IL-11、STAT3及P-STAT3蛋白在胃癌患者组织中的表达及与疾病进展的关系研究
|
摘要
目的分析胃癌组织中IL-11、STAT3及P-STAT3的表达水平与疾病进展的关系。方法选取68例胃癌患者作为研究对象,采用免疫组化检测癌组织及癌旁组织中IL-11、STAT3及P-STAT3的表达水平,统计分析胃癌患者治疗后6个月、12个月的疾病进展情况与癌组织中IL-11、STAT3及P-STAT3表达的相关性。结果胃癌组织中IL-11、STAT3及P-STAT3表达呈阴性(-)、弱阳性表达(+)的比例均低于癌旁组织,而胃癌组织中IL-11、STAT3及P-STAT3表达呈中强阳性表达(++)、强阳性表达(+++)的比例均明显高于癌旁组织,患者治疗后6个月疾病进展的比例为57. 35%,患者治疗后12个月疾病进展的比例为72. 06%,IL-11、STAT3及P-STAT3表达呈中强阳性表达(++)、强阳性表达(+++)的患者,0. 5年、1年的生存率、复发、转移比例均明显高于IL-11、STAT3及P-STAT3表达呈阴性(-)、弱阳性表达(+)患者。结论胃癌组织中IL-11、STAT3及P-STAT3表达呈高表达,并且IL-11、STAT3及P-STAT3表达水平与胃癌疾病进展呈现明显的正相关性。
Objective To analyze the relationship between the expression of IL-11,STAT3 and P-STAT3 and the progression of the disease in gastric cancer. Methods Sixty-eight patients with gastric cancer treated in our hospital from September2015 to September 2016 were enrolled in this study. Immunohistochemistry was used to detect the expression of IL-11,STAT3 and P-STAT3 in cancer tissues and adjacent tissues The levels of IL-11,STAT3 and P-STAT3 in cancer tissues were statistically analyzed after 6 months and 12 months of treatment. Results The expressions of IL-11,STAT3 and P-STAT3 in gastric cancer tissues were negative(-) and weakly positive( +),but the expressions of IL-11,STAT3 and P-STAT3 in gastric cancer tissues were lower than that in paracancerous tissues The positive rates of strong positive expression( + +) and strong positive expression( + + +) were significantly higher than those in paracancerous tissues. The rate of disease progression at 6 months after treatment was 57. 35%. The rate of disease progression at 12 months after treatment Was 72. 06%. The expression of IL-11,STAT3 and P-STAT3 in gastric cancer tissues was moderately strong positive( + +). The patients with strong positive expression( + ++) had 0. 5 years,1 year survival rate,recurrence and metastasis The proportions of IL-11,STAT3 and P-STAT3 were negative(-) and weakly positive( +),respectively. Conclusion The expression of IL-11,STAT3 and P-STAT3 in gastric cancer tissues was highly expressed,and the expression of IL-11,STAT3 and P-STAT3 was positively correlated with the progression of gastric cancer.
Objective To analyze the relationship between the expression of IL-11,STAT3 and P-STAT3 and the progression of the disease in gastric cancer. Methods Sixty-eight patients with gastric cancer treated in our hospital from September2015 to September 2016 were enrolled in this study. Immunohistochemistry was used to detect the expression of IL-11,STAT3 and P-STAT3 in cancer tissues and adjacent tissues The levels of IL-11,STAT3 and P-STAT3 in cancer tissues were statistically analyzed after 6 months and 12 months of treatment. Results The expressions of IL-11,STAT3 and P-STAT3 in gastric cancer tissues were negative(-) and weakly positive( +),but the expressions of IL-11,STAT3 and P-STAT3 in gastric cancer tissues were lower than that in paracancerous tissues The positive rates of strong positive expression( + +) and strong positive expression( + + +) were significantly higher than those in paracancerous tissues. The rate of disease progression at 6 months after treatment was 57. 35%. The rate of disease progression at 12 months after treatment Was 72. 06%. The expression of IL-11,STAT3 and P-STAT3 in gastric cancer tissues was moderately strong positive( + +). The patients with strong positive expression( + ++) had 0. 5 years,1 year survival rate,recurrence and metastasis The proportions of IL-11,STAT3 and P-STAT3 were negative(-) and weakly positive( +),respectively. Conclusion The expression of IL-11,STAT3 and P-STAT3 in gastric cancer tissues was highly expressed,and the expression of IL-11,STAT3 and P-STAT3 was positively correlated with the progression of gastric cancer.
引文
[1]Howlett M,Chalinor HV,Buzzelli JN,et al.Judd LM.IL-11is a parietal cell cytokine that induces atrophic gastritis[J].Gut,2012,61(10):1398-1409.
[2]Putoczki TL,Thiem S,Loving A,et al.Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically[J].Cancer Cell,2013,24(2):257-271.
[3]Onnis B,Fer N,Rapisarda A,et al.Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells[J].JClin Invest,2013,123(4):1615-1629.
[4]Emst M,Najdovska M,Grail D,et al.STAT3 and STAT1mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice[J].J Clin Invest,2008,118(5):1727-1738.
[5]邓立力,赵玉莹,姜秋颖,等.STAT3和p38MAPK在胃癌中的表达及临床意义[J].中国肿瘤,2012,21(5):383-386.
[6]Balakrishnan L,Soman S,Patil YB,et al.IL-11/IL-11RAreceptor mediated signaling:a web accessible knowledgebase[J].cell commun adhes,2013,20(3-4):81-86.
[7]Rhee YH,Jeong SJ,Lee HJ,et al.Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells[J].BMC Cancer,2012,12(1):28.
[8]Liu Z,Xu X,Chen L,et al.Helicobacter pylori Cag A inhibits the expression of Runx3 via Src/MEK/ERK and p38MAPK pathways in gastric epithelial cell[J].J Cell Biochem,2012,113(3):1080-1086.
[9]Ravichandran K,Tyagi A,Deep G,et al.Interleukin-1 beta-induced i NOS expression in human lung carcinoma A549 cells:involvement of STAT and MAPK pathways[J].Indian J Exp Biol,2011,49(11):840-847.
[10]Wolfle SJ,Strebovsky J,Bartz H,et al.PD-L1 expression on tolerogenic APCs is controlled by STAT-3[J].Eur J Immunol,2011,41(2):413-424.
[11]龚代鹏,张竹青,张妍,等.p-STAT3、Survivin和Mcl-1蛋白在胃癌组织中的表达及意义[J].中华临床医师杂志(电子版),2015,9(6):915-920.
[12]Xiong H,Du W,Wang JL,et al.Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer[J].J Mol Med,2012,90(9):1037-1046.
[13]Deng J,Liang H,Zhang R,et al.STAT3 is associated with lymph node metastasis in gastric cancer[J].Tumour Biol,2013,34(5):2791-2800.(下转第203页)
[14]Giraud AS,Menheniott TR,Judd LM.Targeting STAT3 in gastric cancer[J].Expert Opin Ther Targets,2012,16(9):889-901.
[15]Huang S,Chen M,Shen Y,et al.Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells[J].Cancer Lett,2012,315(2):198-205.
[16]Shan T,Cui XJ,Li W,et al.α-Mangostin suppresses human gastric adenocarcinoma cells in vitro via blockade of Stat3signaling pathway[J].Acta Pharmacol Sin,2014,35(8):1065-1073.
[17]Wang YX,Cai H,Jiang G,et al.Silibinin Inhibits Proliferation,Induces Apoptosis and Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells Via STAT3 Pathway Inhibition[J].Asian Pac J Cancer Prev,2014,15(16):6791-6798.
[18]从丽,陶林,赵瑾,等.P-Stat3与胃癌临床病理学关系研究[J].中华实用诊断与治疗杂志,2013,27(6):540-542.
[19]张竹青,卢书明,陈美如,等.胃癌中STAT3、p-STAT3和Bcl-x L的表达及临床意义[J].肿瘤防治研究,2014,41(5):430-433.
[20]Lee SW,Ahn YY,Kim YS,et al.The immunohistochemical expression of STAT3,Bcl-x L,and MMP-2 proteins in colon adenoma and adenocarcinoma[J].Gut Liver,2012,6(1):45-51.
[2]Putoczki TL,Thiem S,Loving A,et al.Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically[J].Cancer Cell,2013,24(2):257-271.
[3]Onnis B,Fer N,Rapisarda A,et al.Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells[J].JClin Invest,2013,123(4):1615-1629.
[4]Emst M,Najdovska M,Grail D,et al.STAT3 and STAT1mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice[J].J Clin Invest,2008,118(5):1727-1738.
[5]邓立力,赵玉莹,姜秋颖,等.STAT3和p38MAPK在胃癌中的表达及临床意义[J].中国肿瘤,2012,21(5):383-386.
[6]Balakrishnan L,Soman S,Patil YB,et al.IL-11/IL-11RAreceptor mediated signaling:a web accessible knowledgebase[J].cell commun adhes,2013,20(3-4):81-86.
[7]Rhee YH,Jeong SJ,Lee HJ,et al.Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells[J].BMC Cancer,2012,12(1):28.
[8]Liu Z,Xu X,Chen L,et al.Helicobacter pylori Cag A inhibits the expression of Runx3 via Src/MEK/ERK and p38MAPK pathways in gastric epithelial cell[J].J Cell Biochem,2012,113(3):1080-1086.
[9]Ravichandran K,Tyagi A,Deep G,et al.Interleukin-1 beta-induced i NOS expression in human lung carcinoma A549 cells:involvement of STAT and MAPK pathways[J].Indian J Exp Biol,2011,49(11):840-847.
[10]Wolfle SJ,Strebovsky J,Bartz H,et al.PD-L1 expression on tolerogenic APCs is controlled by STAT-3[J].Eur J Immunol,2011,41(2):413-424.
[11]龚代鹏,张竹青,张妍,等.p-STAT3、Survivin和Mcl-1蛋白在胃癌组织中的表达及意义[J].中华临床医师杂志(电子版),2015,9(6):915-920.
[12]Xiong H,Du W,Wang JL,et al.Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer[J].J Mol Med,2012,90(9):1037-1046.
[13]Deng J,Liang H,Zhang R,et al.STAT3 is associated with lymph node metastasis in gastric cancer[J].Tumour Biol,2013,34(5):2791-2800.(下转第203页)
[14]Giraud AS,Menheniott TR,Judd LM.Targeting STAT3 in gastric cancer[J].Expert Opin Ther Targets,2012,16(9):889-901.
[15]Huang S,Chen M,Shen Y,et al.Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells[J].Cancer Lett,2012,315(2):198-205.
[16]Shan T,Cui XJ,Li W,et al.α-Mangostin suppresses human gastric adenocarcinoma cells in vitro via blockade of Stat3signaling pathway[J].Acta Pharmacol Sin,2014,35(8):1065-1073.
[17]Wang YX,Cai H,Jiang G,et al.Silibinin Inhibits Proliferation,Induces Apoptosis and Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells Via STAT3 Pathway Inhibition[J].Asian Pac J Cancer Prev,2014,15(16):6791-6798.
[18]从丽,陶林,赵瑾,等.P-Stat3与胃癌临床病理学关系研究[J].中华实用诊断与治疗杂志,2013,27(6):540-542.
[19]张竹青,卢书明,陈美如,等.胃癌中STAT3、p-STAT3和Bcl-x L的表达及临床意义[J].肿瘤防治研究,2014,41(5):430-433.
[20]Lee SW,Ahn YY,Kim YS,et al.The immunohistochemical expression of STAT3,Bcl-x L,and MMP-2 proteins in colon adenoma and adenocarcinoma[J].Gut Liver,2012,6(1):45-51.